CTLA4 and renal cell carcinoma: Of note, in our multicenter RCC-ICB cohort, CTLA4 promoter hypomethylation predicted ICB treatment success, which also translated into prolonged PFS and OS after ICB treatment initiation, thereby counteracting its negative prognostic value in primary ccRCC at initial diagnosis.